Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon

* Inclusion Criteria: * Age 21 to 80 years old with type 1 diabetes for at least one year. * Diabetes managed using an insulin infusion pump using rapid-acting insulin such as insulin aspart (NovoLog), insulin lispro (Humalog), or insulin glulisine (Apidra) for at least one week prior to enrollment. * Alcohol exposure on at least one occasion in the last year consisting of at least 4 drinks in one sitting. * Exclusion Criteria: * Unable to provide informed consent. * Unable to comply with study procedures. * Unable to refrain from the consumption of alcohol at least 24 hours prior to study start. * Current participation in another diabetes-related clinical trial that, in the judgment of the principle investigator, will compromise the results of the clamp study or the safety of the subject. * Pregnancy (positive urine HCG), breast feeding, plan to become pregnant in the immediate future, or sexually active without use of contraception. * Aldehyde dehydrogenase deficiency as determined by a screening questionnaire * End stage renal disease on dialysis (hemodialysis or peritoneal dialysis). * History of pheochromocytoma (because glucagon has been reported to precipitate hypertensive crisis in the setting of pheochromocytoma). Fractionated metanephrines will be tested in patients with a history increasing the risk for a catecholamine secreting tumor: * Paroxysms of tachycardia, pallor, or headache. Personal or family history of MEN 2A, MEN 2B, neurofibromatosis, or von Hippel-Lindau disease, Episodic or treatment of refractory (requiring 4 or more medications to achieve normotension) hypertension. * History of adverse reaction to glucagon (including allergy) besides nausea, vomiting, or headache. * Inadequate venous access as determined by study nurse or physician at time of screening. * Liver failure or cirrhosis * Hemoglobin \< 12 gm/dl. * History of problem drinking or alcoholism, regardless of whether active or in remission. * Use of benzodiazepines or barbiturates or opiates or other central nervous system depressant drugs that could act synergistically with ethanol to lower the level of consciousness * Any other factors that, in the judgment of the principal investigator, would interfere with the safe completion of the study procedures.